REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1

Historical Holders from Q1 2021 to Q1 2025

Type / Class
Debt / NOTE 1.750% 2/1
All holders as of 31 Mar 2025
Q1 2025
Total 13F principal, excl. options
0
Holdings value
$0
Number of holders
0
Number of sells
-17
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1

Period Principal Value Change Price Investors
2025 Q1 0 $0 -$237,500,723 0
2024 Q4 188,131,543 $237,976,348 -$7,868,518 $0.9574 18
2024 Q3 197,744,550 $176,846,616 +$6,712,325 $0.8544 22
2024 Q2 212,353,242 $139,496,291 -$15,500,337 $0.656 21
2024 Q1 231,994,242 $202,469,009 -$23,078,977,898 $0.7275 22
2023 Q4 264,943,000 $201,238,321 +$13,097,322 $0.7594 23
2023 Q3 245,718,242 $198,931,644 -$16,150,064 $0.8047 29
2023 Q2 254,646,421 $269,088,244 -$13,759,672 $1.06 28
2023 Q1 265,005,282 $330,401,198 +$43,557,319 $1.23 28
2022 Q4 253,368,000 $234,923,888 -$49,050,168 $0.923 24
2022 Q3 323,081,000 $353,201,545 +$9,517,776 $1.09 28
2022 Q2 273,236,000 $226,785,000 +$15,533,536 $0.8156 18
2022 Q1 249,383,000 $239,572,000 -$21,994,040 $0.9406 19
2021 Q4 252,502,187 $225,617,587 -$17,407,568 $0.883 19
2021 Q3 282,389,000 $325,197,920 +$23,117,160 $1.15 21
2021 Q2 261,971,087 $306,514,595 +$5,146,358 $1.17 25
2021 Q1 265,777,587 $298,923,677 +$298,923,677 $1.12 27